Close

Anti-TPTE TCR-NK Cells (XS-0623-ZP191)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The genetically modified anti-TPTE TCR-NK cell is designed to target to the specific epitope-HLA complex. The TCR-NK is expected to show antigen-specific cytotoxicity against TPTE antigen via the introduced TCR were successfully produced.

  Add to Cart

Specifications

  • Cell Type
  • TCR-NK
  • Host Cell Type
  • Primary NK cells

TCR Design

  • Target
  • TPTE
  • Common Name
  • TPTE
  • Target Species
  • Human
  • TCR-Host Animal
  • Human
  • Vector Name
  • pCDTCR1
  • Vector length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
Sub CAT. HLA TCR Clone Epitope  
XS-0623-ZP191-SUB1 HLA-DRB1*0701 TCRCD4-TPT#11 ILADLIFTDSKLYIPLEYR
XS-0623-ZP191-SUB2 HLA-DRB1*1401 TCRCD4-TPT#13 WLHTSFIENNRLYLPKNEL
XS-0623-ZP191-SUB3 HLA-DRB5*0202 TCRCD4-TPT#17 IFFDIKLLRNIPRWTHLLR
XS-0623-ZP191-SUB4 HLA-DRB3*0301 TCRCD4-TPT#27 IKLLRNIPRWTHLLR
XS-0623-ZP191-SUB5 HLA-DRB5*0202 TCRCD4-TPT#33 KLIRRRVSENKRRYT
XS-0623-ZP191-SUB6 HLA-DRB1*1601 TCRCD4-TPT#38 NHYRVYNLCSERAYD
XS-0623-ZP191-SUB7 HLA-DRB4*1101 TCRCD4-TPT#4 NWNLPPRRILFIKHFIIYS
XS-0623-ZP191-SUB8 HLA-DRB1*1301 TCRCD4-TPT#42 RFLDKKHRNHYRVYN
XS-0623-ZP191-SUB9 HLA-DRB1*1501 TCRCD4-TPT#45 ILFIKHFIIYSIPRY
XS-0623-ZP191-SUB10 HLA-DRB1*1501 TCRCD4-TPT#48 DVVYIFFDIKLLRNI
XS-0623-ZP191-SUB11 HLA-DRB1*1501 TCRCD4-TPT#49 YVAYFAQVKHLYNWNLPPR
XS-0623-ZP191-SUB12 HLA-DRB1*1401 TCRCD4-TPT#5 KHFIIYSIPRYVRDLKIQI
XS-0623-ZP191-SUB13 HLA-DRB1*1301 TCRCD4-TPT#51 KLIRRRVSENKRRYT
XS-0623-ZP191-SUB14 HLA-DRB1*1501 TCRCD4-TPT#52 DSKLYIPLEYRSISLAIAL
XS-0623-ZP191-SUB15 HLA-DQB1*0602/03 TCRCD4-TPT#54 SPISESVLARLSKFE
XS-0623-ZP191-SUB16 HLA-DRB1*1301 TCRCD4-TPT#55 IFFDIKLLRNIPRWTHLLR
XS-0623-ZP191-SUB17 HLA-DRB1*1501 TCRCD4-TPT#57 IKKIVHSIVSSFAFG
XS-0623-ZP191-SUB18 HLA-DRB1*1301 TCRCD4-TPT#59 VLLRVFVERRQQYFS
XS-0623-ZP191-SUB19 HLA-DRB1*1401 TCRCD4-TPT#6 SPISESVLARLSKFEVEDA
XS-0623-ZP191-SUB20 HLA-DRB1*1501 TCRCD4-TPT#67 DVVYIFFDIKLLRNI
XS-0623-ZP191-SUB21 HLA-DQA1*0102/DQB1*0602 TCRCD4-TPT#76 VLDNITTDKILIDVF
XS-0623-ZP191-SUB22 HLA-DRB1*1301 TCRCD4-TPT#77 KHFIIYSIPRYVRDLKIQI
XS-0623-ZP191-SUB23 HLA-DRB1*1301 TCRCD4-TPT#78 RRVSENKRRYTRDGF
XS-0623-ZP191-SUB24 HLA-DRB1*1501 TCRCD4-TPT#79 DVVYIFFDIKLLRNI
XS-0623-ZP191-SUB25 HLA-DRB3*0201/2 TCRCD4-TPT#8 IKLLRNIPRWTHLLR
XS-0623-ZP191-SUB26 HLA-DRB1*1301 TCRCD4-TPT#82 PPRRILFIKHFIIYS
XS-0623-ZP191-SUB27 HLA-DRB1*1301 TCRCD4-TPT#87 IFFDIKLLRNIPRWTHLLR
XS-0623-ZP191-SUB28 HLA-DRB1*1501 TCRCD4-TPT#91 DVVYIFFDIKLLRNI
XS-0623-ZP191-SUB29 HLA-DRB1*0701 TCRCD4-TPT#99 YIPLEYRSISLAIAL
XS-0623-ZP191-SUB30 HLA-B3501 TCRCD8-TPT#3 YPSDFAVEI
XS-0623-ZP191-SUB31 HLA-B*0702 TCRCD8-TPT#35 PRWTHLLRL

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-TPTE TCR-NK Cells (XS-0623-ZP191). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.